EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Reassessment of the Clinical Utility of 68 Ga‐DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors

Orjola Prela, Brennen Caveney, Myla Strawderman, David Linehan, Eva Galka, Luke Schoeniger, Aram Hezel, Nabeel Badri, Darren R Carpizo

Journal of Surgical Oncology · 2025

DOI: 10.1002/jso.28061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Orjola Prela und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of General Surgery, University of Rochester, Rochester, New York, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) are a rare and biologically diverse group of tumors that are challenging to image. 68 Ga‐DOTATATE PET/CT is the most sensitive imaging tool for these tumors, and while its use has increased over time, its clinical impact remains unclear, particularly for clinical scenarios involving surveillance after treatment. We sought to reassess its clinical utility across all stages.

Methods

Retrospective study of pathologically confirmed GEP‐NET patients between 1/1/2020 and 9/1/2022 at a tertiary care center. Demographic, clinical, and radiographic data were analyzed. The primary objective was to determine if PET/CT use was associated with a change in clinical management. The secondary objective was to determine if PET/CT was superior in identifying primary or metastatic lesions compared to traditional imaging.

Results

One hundred twenty‐four patients with GEP‐NETs underwent 207 PET/CT scans. The majority of scans were obtained for disease surveillance (70.2%) or staging (37.9%), and the remaining (3.2%) were used to aid in diagnosis or before PRRT initiation (3.2%). Following PET/CT scan, 51 patients (41.1%) had a change in clinical management, with change being higher among those with metastatic disease (44.9% vs. 14.5%). Of the 124, 72 patients had traditional imaging available for comparison. In this subgroup, 34 patients (47.2%) had new lesions identified on PET/CT that were not identified using traditional imaging resulting in a change in management in 79.4% favoring patients with M1 versus M0 disease (26.9% M0 vs. 58.7% M1, p = 0.010).

Conclusion

68 Ga‐DOTATATE PET/CT imaging is clinically most useful for initial staging and in surveillance and monitoring response to therapy in the metastatic setting. It is least useful for surveillance in the early‐stage setting and does not support its use following curative intent surgery. It remains superior to unlabeled imaging in sensitivity and the additional disease burden detected is highly likely to change management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPositron Emission Tomography Computed TomographyPancreatic NeoplasmsStomach NeoplasmsIntestinal NeoplasmsOrganometallic CompoundsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultRadiopharmaceuticalsGallium RadioisotopesAged, 80 and overFollow-Up Studies

Stichwörter der Autor:innen

Gallium‐68 Dotatate PET/CTclinical utilitygastroenteropancreatic neuroendocrine tumorsmanagement change

Substanzen

gallium Ga 68 dotatateOrganometallic CompoundsRadiopharmaceuticalsGallium Radioisotopes

Autor:innen und Institutionen

  • Department of Surgery, Division of General Surgery, University of Rochester, Rochester, New York, USA.
  • University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
  • Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
  • Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
  • Department of Surgery, Division of Surgical Oncology, University of Rochester, Rochester, New York, USA.
  • Department of Medicine, Division of Hematology/Oncology, University of Rochester, Rochester, New York, USA.

Zitieren

APA

Prela, O., Caveney, B., Strawderman, M., Linehan, D., Galka, E., Schoeniger, L., Hezel, A., Badri, N., & Carpizo, D. R. (2025). A Reassessment of the Clinical Utility of 68 Ga‐DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Journal of Surgical Oncology. https://doi.org/10.1002/jso.28061

Vancouver

Prela O, Caveney B, Strawderman M, Linehan D, Galka E, Schoeniger L, et al. A Reassessment of the Clinical Utility of 68 Ga‐DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Journal of Surgical Oncology. 2025. doi:10.1002/jso.28061

BibTeX
@article{Prela2025,
  author = {Prela, Orjola and Caveney, Brennen and Strawderman, Myla and Linehan, David and Galka, Eva and Schoeniger, Luke and Hezel, Aram and Badri, Nabeel and Carpizo, Darren R},
  title = {A Reassessment of the Clinical Utility of 68 Ga‐DOTATATE PET/CT in Patients With Gastroenteropancreatic Neuroendocrine Tumors},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1002/jso.28061}
}
Kostenlos starten →